Skip to main content

Table 2 PICU therapeutic interventions between survivors and non-survivors

From: A case series of children with adenovirus pneumonia: three-year experiences in a tertiary PICU

  Survivors (n = 56) Non-survivors (n = 11) Total (n = 67) p value
Median of PICU stay, days 11 (7.75, 18) 15 (11, 19.5) 11 (8, 18) 0.861
Median of hospital stay, days 22.5 (16, 34.25) 17 (16, 23.5) 22 (16, 31) 0.124
Co-morbidity, n (%)
 ARDS 27 (48.21%) 9 (81.82%) 36 (53.73%) 0.041
 Liver dysfunction 21 (31.34%) 10 (90.9%) 31 (46.27%) 0.001
 AKI 4 (7.14%) 5 (45.45%) 9 (13.43%) 0.001
 shock 42 (75%) 10 (90.9%) 52 (77.61%) 0.247
 GI dysfunction 31 (55.36%) 11 (100%) 42 (62.69%) 0.005
PICU and hospital therapies, n (%)
 Invasive Mechanical ventilation 51 (91.07%) 11 (100%) 62 (92.54%) 0.303
 CRRT/RRT 11 (19.64%) 8 (72.73%) 19 (28.36%) <0.001
 ECMO 6 (10.71%) 3 (37.5%) 9 (13.43%) 0.141
 Prone positioning, n (%) 15 (26.79%) 4 (36.36%) 19 (28.36%) 0.519
 Neuromuscular blockade, n (%) 22 (39.29%) 8 (72.73%) 30 (44.78%) 0.041
 Vasoactive use 48 (85.71%) 10 (90.9%) 58 (86.57%) 0.644
 diuretics use 43 (76.79%) 8 (72.73%) 51 (76.12%) 0.773
 Steroids use 55 (98.21%) 11 (100%) 66 (98.51%) 0.655
 IV immunoglobulin 50 (89.29%) 10 (90.9%) 60 (89.55%) 0.872
 Parenteral nutrition 12 (21.43%) 10 (90.9%) 22 (32.84%) <0.001
 Packed red blood cell perfusion 28 (50%) 10 (90.9%) 38 (56.72%) 0.012
Nosocomial infenctiona, n (%) 15 (26.79%) 7 (63.64%) 22 (32.84%) 0.017
 bacterial 15 (26.79%) 7 (63.64%) 22 (32.84%)  0.043
 fungal 4 (7.14%) 1 (9.09%) 5 (7.46%) 0.687
  1. aparts of patients complicated with bacteria, mycoplasma pneumoniae or fungi in nosocomial infection or co-infection